Top Institutions in Oncology - Uveal Melanoma and Cancer Genomics
Leading institutions employ comprehensive genome-wide CRISPR–Cas9 screening combined with multi-omics profiling (genomic, transcriptomic, proteomic) and functional validation in cell line models and patient tumor samples to identify synthetic lethal interactions and druggable targets in uveal melanoma.
-
#1
Wellcome Sanger Institute
Hinxton, Cambridgeshire
Pioneers in large-scale CRISPR–Cas9 screening and integrative multi-omics approaches, the Wellcome Sanger Institute led the landmark study identifying synthetic lethality in uveal melanoma, demonstrating expertise in functional cancer genomics and translational research.
-
#2
Broad Institute of MIT and Harvard
Cambridge, Massachusetts
The Broad Institute hosts the DepMap project, a comprehensive cancer dependency map using CRISPR screening across hundreds of cell lines, providing critical data on gene essentiality and synthetic lethality relevant to uveal melanoma and other cancers.
-
#3
The University of Texas MD Anderson Cancer Center
Houston, Texas
MD Anderson is a leading center for ocular melanoma clinical trials and translational research, with extensive expertise in developing targeted therapies and immunotherapies for uveal melanoma and other melanomas.
-
#4
Memorial Sloan Kettering Cancer Center
New York, New York
MSKCC integrates genomic profiling with clinical oncology to identify actionable targets in melanoma subtypes, including uveal melanoma, and advances precision medicine approaches through early-phase clinical trials.
-
#5
National Cancer Institute (NCI)
Bethesda, Maryland
The NCI supports and coordinates large-scale cancer genomics projects and drug discovery efforts, including funding and resources for uveal melanoma research and synthetic lethality studies.
